Home-Based Titration with Duodenal Infusion of Levodopa-Carbidopa Intestinal Gel in People with Parkinson’s Disease: An Observational Feasibility Study

Table 1

Descriptive data (including the 2 dropouts) and clinical characteristics of all the participants using descriptive statistics.

Descriptive data	Mean/SD	Min/max
Age	74.0/5.0	64/81
Years with PD	12.9/4.6	6/20
MoCA score	23.1/4.3	16/30
Barthel score (before titration)	17.2/2.8	11/20
Charlson’s Comorbidity Index score	3.25/1.2	1/6
Levodopa equivalent dose (LED) at baseline	1187.2/356.3	550/1850
LED at the end of the HBT program (day 14)	1097.6/302.5	565/1578
Hoehn and Yahr scale score	N	%
H&Y = 3	8	75
H&Y = 4	4	25
Sex
Female	5	42
Male	7	58
Housing status
Living alone	2	17
Cohabitant	8	66
Nursing home	2	17
Daily function
Independent of help	4	33
Dependent on help	8	67
Clinical variables at baseline	Mean/SD	Min-maximum
NMSQuest score (0–95)	67.5/22.3	43/81
UPDRS-III score (0–132)	43.6/16.4	27/73
Evaluation outcomes	Mean/SD	Min-maximum
Primary outcome
Evaluation score (PwPs) (0–40)	36.2/3.9	27/40
Evaluation score (caregivers) (0–40)	31.8/7.2	25/39
Secondary outcomes
Hours with dyskinesia (per day) during titration	2.4/1.8	0/5.3
Hours with off (per day) during titration	8.7/4.1	4/15.5
Time (minutes) spent in PwP’s home (HCP)	93.4/35.2	35/180
Number of video or phone calls to PwP	3.2/0.3	3/4